Molecular Imaging of Brain Tumors with Radiolabeled Choline PET

Overview

Journal Neurosurg Rev

Specialty Neurosurgery

Date 2016 May 28

PMID 27230829

Citations 14

Authors

Ferdinando Franco Calabria

Manlio Barbarisi

Vincenzo Gangemi

Giovanni Grillea

Giuseppe Lucio Cascini

Affiliations

Soon will be listed here.

Abstract

Several positron emission tomography (PET) radiopharmaceuticals have been emerged in the last decade as feasible in the management of brain lesions, due to the low performance in this field of the 18F-fluoro-deoxyglucose (18F-FDG), for its high physiological gradient of distribution in the brain. Beyond its usefulness in prostate cancer imaging, the radiolabeled choline is becoming a promising tool in diagnosing benign and malignant lesions of the brain, due to a very low rate of distribution in normal white and grey matters. The aim of our review was to assess the real impact of the radiolabeled choline PET/CT in the management of brain benign lesions, brain tumors, and metastases. Furthermore, emphasis was given to the comparison between the radiolabeled choline and the other radiopharmaceuticals in this field. A literature review was performed. The radiolabeled choline is useful in the management of patients with suspected brain tumor relapse, especially in association with magnetic resonance imaging (MRI), with caution regarding its intrinsic characteristic of non-tumor-specific tracer. For the same reason, it is not useful in the early evaluation of brain lesions. Similar results are reported for other radiopharmaceuticals. The inclusion of the head in the whole-body scans for somatic tumors is necessary to ensure metastases in the brain or choline-avid benign lesions.

Citing Articles

Hybrid PET/MRI in Cerebral Glioma: Current Status and Perspectives.

Langen K, Galldiks N, Mauler J, Kocher M, Filss C, Stoffels G Cancers (Basel). 2023; 15(14).

PMID: 37509252 PMC: 10377176. DOI: 10.3390/cancers15143577.

Mapping of exogenous choline uptake and metabolism in rat glioblastoma using deuterium metabolic imaging (DMI).

Ip K, Thomas M, Behar K, de Graaf R, De Feyter H Front Cell Neurosci. 2023; 17:1130816.

PMID: 37187610 PMC: 10175635. DOI: 10.3389/fncel.2023.1130816.

Imaging biomarkers for clinical applications in neuro-oncology: current status and future perspectives.

Chiu F, Yen Y Biomark Res. 2023; 11(1):35.

PMID: 36991494 PMC: 10053808. DOI: 10.1186/s40364-023-00476-7.

Metabolic activity grows in human cancers pushed by phenotypic variability.

Bosque J, Calvo G, Molina-Garcia D, Perez-Beteta J, Garcia Vicente A, Perez-Garcia V iScience. 2023; 26(3):106118.

PMID: 36843844 PMC: 9950952. DOI: 10.1016/j.isci.2023.106118.

Investigational PET tracers in neuro-oncology-What's on the horizon? A report of the PET/RANO group.

Galldiks N, Langen K, Albert N, Law I, Kim M, Villanueva-Meyer J Neuro Oncol. 2022; 24(11):1815-1826.

PMID: 35674736 PMC: 9629449. DOI: 10.1093/neuonc/noac131.

References

Rathore C, Dickson J, Teotonio R, Ell P, Duncan J . The utility of 18F-fluorodeoxyglucose PET (FDG PET) in epilepsy surgery. Epilepsy Res. 2014; 108(8):1306-14. DOI: 10.1016/j.eplepsyres.2014.06.012. View

Tripathi M, Sharma R, Dsouza M, Jaimini A, Panwar P, Varshney R . Comparative evaluation of F-18 FDOPA, F-18 FDG, and F-18 FLT-PET/CT for metabolic imaging of low grade gliomas. Clin Nucl Med. 2010; 34(12):878-83. DOI: 10.1097/RLU.0b013e3181becfe0. View

Gulyas B, Nyary I, Borbely K . FDG, MET or CHO? The quest for the optimal PET tracer for glioma imaging continues. Nat Clin Pract Neurol. 2008; 4(9):470-1. DOI: 10.1038/ncpneuro0863. View

Gulyas B, Halldin C . New PET radiopharmaceuticals beyond FDG for brain tumor imaging. Q J Nucl Med Mol Imaging. 2012; 56(2):173-90. View

Cascini G, Restuccia A, De Vincenti T, Manti F, Calabria F . A vascular lesion mimicking a primitive brain tumour in a patient examined by (18)F-choline PET/CT and MRI. Rev Esp Med Nucl Imagen Mol. 2015; 34(5):335-6. DOI: 10.1016/j.remn.2015.02.003. View

Mertens K, Slaets D, Lambert B, Acou M, de Vos F, Goethals I . PET with (18)F-labelled choline-based tracers for tumour imaging: a review of the literature. Eur J Nucl Med Mol Imaging. 2010; 37(11):2188-93. DOI: 10.1007/s00259-010-1496-z. View

Gunia S, Ecke T, Wohlfarth B, Koch S, Erbersdobler A . Dural metastases from disseminated prostate cancer clinically mimicking a benign reactive condition of the dura: case report and review of the literature. Urol Int. 2010; 86(2):239-41. DOI: 10.1159/000321272. View

Manohar K, Bhattacharya A, Mittal B . Low positive yield from routine inclusion of the brain in whole-body 18F-FDG PET/CT imaging for noncerebral malignancies: results from a large population study. Nucl Med Commun. 2013; 34(6):540-3. DOI: 10.1097/MNM.0b013e32836066c0. View

Shinoura N, Nishijima M, Haisa T, Yamamoto H, Fujii K, Mitsui I . Brain tumors: detection with C-11 choline PET. Radiology. 1997; 202(2):497-503. DOI: 10.1148/radiology.202.2.9015080. View

10.

Fallanca F, Giovacchini G, Picchio M, Bettinardi V, Messa C, Fazio F . Incidental detection by [11C]choline PET/CT of meningiomas in prostate cancer patients. Q J Nucl Med Mol Imaging. 2009; 53(4):417-21. View

11.

van Waarde A, Jager P, Ishiwata K, Dierckx R, Elsinga P . Comparison of sigma-ligands and metabolic PET tracers for differentiating tumor from inflammation. J Nucl Med. 2006; 47(1):150-4. View

12.

Ohtani T, Kurihara H, Ishiuchi S, Saito N, Oriuchi N, Inoue T . Brain tumour imaging with carbon-11 choline: comparison with FDG PET and gadolinium-enhanced MR imaging. Eur J Nucl Med. 2001; 28(11):1664-70. DOI: 10.1007/s002590100620. View

13.

Calabria F, Cascini G . Current status of 18F-DOPA PET imaging in the detection of brain tumor recurrence. Hell J Nucl Med. 2015; 18(2):152-6. DOI: 10.1967/s0024499100211. View

14.

Bieze M, Bennink R, El-Massoudi Y, Phoa S, Verheij J, Beuers U . The use of 18F-fluoromethylcholine PET/CT in differentiating focal nodular hyperplasia from hepatocellular adenoma: a prospective study of diagnostic accuracy. Nucl Med Commun. 2012; 34(2):146-54. DOI: 10.1097/MNM.0b013e32835afe62. View

15.

Tian M, Zhang H, Oriuchi N, Higuchi T, Endo K . Comparison of 11C-choline PET and FDG PET for the differential diagnosis of malignant tumors. Eur J Nucl Med Mol Imaging. 2004; 31(8):1064-72. DOI: 10.1007/s00259-004-1496-y. View

16.

Bertagna F, Bosio G, Pinelli L, Treglia G, Giubbini R . Incidental 11C-choline PET/CT brain uptake due to meningioma in a patient studied for prostate cancer: correlation with MRI and imaging fusion. Clin Nucl Med. 2013; 38(11):e435-7. DOI: 10.1097/RLU.0b013e31827a22f7. View

17.

Kwee S, Ko J, Jiang C, Watters M, Coel M . Solitary brain lesions enhancing at MR imaging: evaluation with fluorine 18 fluorocholine PET. Radiology. 2007; 244(2):557-65. DOI: 10.1148/radiol.2442060898. View

18.

Masala S, Schillaci O, Bartolucci A, Calabria F, Mammucari M, Simonetti G . Metabolic and clinical assessment of efficacy of cryoablation therapy on skeletal masses by 18F-FDG positron emission tomography/computed tomography (PET/CT) and visual analogue scale (VAS): initial experience. Skeletal Radiol. 2010; 40(2):159-65. DOI: 10.1007/s00256-010-0960-y. View

19.

Schillaci O, Calabria F, Tavolozza M, Ciccio C, Carlani M, Caracciolo C . 18F-choline PET/CT physiological distribution and pitfalls in image interpretation: experience in 80 patients with prostate cancer. Nucl Med Commun. 2009; 31(1):39-45. DOI: 10.1097/mnm.0b013e328330adc5. View

20.

Niccoli-Asabella A, Notaristefano A, Garribba M, Rubini D, Ferrari C, Rubini G . [The PET/CT with 18F-fluorocholine in the diagnosis of gliomatosis cerebri type 2]. Recenti Prog Med. 2013; 104(2):73-5. DOI: 10.1701/1241.13709. View